Search results for "antidepressant"

showing 10 items of 161 documents

The Effect of Age, Sex, Smoking and Co-Medication on Serum Levels of Venlafaxine and O-Desmethylvenlafaxine under Naturalistic Conditions

2012

Venlafaxine (VEN) is a modern antidepressant which exerts both serotonin and norepinephrine reuptake inhibition. In this study we examined the influence of age, sex, smoking, and co-medication on serum levels of VEN and its metabolite O-desmethylvenlafaxine (ODVEN) in patients treated with VEN under naturalistic conditions.We retrospectively evaluated 478 TDM analyses of VEN requested in the Pychiatric University Hospitals of Mainz, Regensburg, and Würzburg. The determination of serum levels was performed by virtually identical chromatographic methods in the TDM laboratories of the participating hospitals.Serum levels varied widely on each dose level. Women had about 30% higher dose-correct…

AdultMalemedicine.medical_specialtyAdolescentVenlafaxine HydrochlorideVenlafaxinePharmacokineticsDesvenlafaxine SuccinateInternal medicinemedicineHumansPharmacology (medical)DosingAgedRetrospective StudiesAged 80 and overSex Characteristicsbusiness.industrySmokingAge FactorsVenlafaxine HydrochlorideRetrospective cohort studyGeneral MedicineMiddle AgedCyclohexanolsPsychiatry and Mental healthAnesthesiaVenAntidepressive Agents Second-GenerationAntidepressantDrug Therapy CombinationFemaleDrug Monitoringbusinessmedicine.drugSex characteristicsPharmacopsychiatry
researchProduct

Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants

2018

Abstract Background Treatment-emergent affective switch (TEAS), including treatment-emergent mania (TEM), carry significant burden in the clinical management of bipolar depression, whereas the use of antidepressants raises both efficacy, safety and tolerability concerns. The present study assesses the prevalence and clinical correlates of TEM in selected sample of Bipolar Disorder (BD) Type-II (BD-II) acute depression outpatients. Methods Post-hoc analysis of the clinical and psychopathological features associated with TEM among 91 BD-II depressed outpatients exposed to antidepressants. Results Second-generation antipsychotics (SGA) (p = .005), lithium (≤ .001), cyclothymic/irritable/hypert…

AdultMalemedicine.medical_specialtyBipolar DisorderAdolescentLithium (medication)media_common.quotation_subjectTreatment-emergent-maniaAntidepressantGastroenterologyYoung Adult03 medical and health sciencesBipolar Disorder (BD) Antidepressant Depression Treatment-emergent-mania0302 clinical medicineInternal medicineRecall biasOutpatientsmedicineHumansBipolar disorderAgedmedia_commonAntidepressant; Bipolar Disorder (BD); Depression; Treatment-emergent-mania; Clinical Psychology; Psychiatry and Mental Healthbusiness.industryDepressionMiddle Agedmedicine.diseaseBipolar Disorder (BD)Antidepressive Agents030227 psychiatryClinical PsychologyCross-Sectional StudiesTreatment OutcomeTolerabilityPsychiatry and Mental HealthAntidepressantDrug Therapy CombinationFemaleTemperamentmedicine.symptombusinessMania030217 neurology & neurosurgeryAntipsychotic AgentsPsychopathologymedicine.drug
researchProduct

Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders.

2012

Whether responses to antidepressants differ in bipolar and unipolar depression remains unresolved.We analyzed patient characteristics and outcomes of antidepressant treatment of 1036 depressed patients with bipolar-I or bipolar-II disorder, or unipolar major depression, using bivariate and multivariate methods and survival analysis, testing the hypothesis that responses would be superior in unipolar depression.Antidepressants were given to 84.8% (878/1036) of depressed patients: 58.9% of 93 bipolar-I, 80.1% of 117 bipolar-II, and 91.3% of 668 unipolar disorder cases. The 158 not given antidepressants had more manias/year, spent more months in mania and depression, and were far more likely t…

AdultMalemedicine.medical_specialtyBipolar DisorderMonoamine Oxidase InhibitorsAntidepressive Agents Tricyclicbehavioral disciplines and activitiesInternal medicinemental disordersmedicineHumansBipolar disorderPsychiatrySurvival analysisDepression (differential diagnoses)Depressive Disorder MajorManic MoodMiddle Agedmedicine.diseaseAntidepressive AgentsPsychiatry and Mental healthMoodTreatment OutcomeMajor depressive disorderAntidepressantFemalemedicine.symptomPsychologyManiaSelective Serotonin Reuptake InhibitorsActa psychiatrica Scandinavica
researchProduct

A combined marker of early non-improvement and the occurrence of melancholic features improve the treatment prediction in patients with Major Depress…

2017

Abstract Background Early Improvement of depressive symptoms within two weeks of antidepressant treatment is a highly sensitive but less specific predictor of later treatment outcome. The aim of this study was to identify clinical features at treatment initiation which are associated with early improvement and non-improvement as well as to identify variables predicting non-remission in patients showing an early improvement. Methods 889 patients with a major depressive episode according to DSM-IV who had participated in an antidepressant treatment trial served as study sample. Clinical predictors (demographic variables, psychopathology, comorbid disorders) were analysed in 698 (79%) early im…

AdultMalemedicine.medical_specialtyComorbidityAvoidant personality disorderPatient ReadmissionSeverity of Illness IndexSuicidal Ideation03 medical and health sciences0302 clinical medicineRisk FactorsRating scaleInternal medicinemedicineHumansMajor depressive episodePsychiatryAtypical depressionDepression (differential diagnoses)Depressive Disorder Majorbusiness.industryMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthClinical PsychologyTreatment OutcomeMajor depressive disorderAntidepressantFemalemedicine.symptombusiness030217 neurology & neurosurgeryPsychopathologyJournal of Affective Disorders
researchProduct

Body mass index (BMI) in major depressive disorder and its effects on depressive symptomatology and antidepressant response

2019

Obesity is one of the most prevalent somatic comorbidities of Major Depressive Disorder (MDD). We aimed to investigate the relationship between body mass index (BMI) and MDD, the symptomatology of the disorder as well as the outcome of antidepressant treatment.Early medication change (EMC) trial participants with BMI measurement (n = 811) were categorized according to WHO-criteria in normal or low weight (BMI  25), overweight (25- 30), and obese (≥30). Depression severity and BMI was assessed in weekly intervals up to 8 weeks. BMI at baseline and course of BMI during the study were investigated in linear regression models as possible moderators of therapy response. Possible moderators such …

AdultMalemedicine.medical_specialtyComorbidityOverweightWeight GainBody Mass IndexDepressive symptomatology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansObesityDepression (differential diagnoses)Depressive Disorder Majorbusiness.industryMiddle Agedmedicine.diseaseObesityAntidepressive Agents030227 psychiatryPsychiatry and Mental healthClinical PsychologyAntidepressantMajor depressive disorderFemalemedicine.symptombusinessWeight gainBody mass index030217 neurology & neurosurgeryJournal of Affective Disorders
researchProduct

State dependent posterior hippocampal volume increases in patients with major depressive disorder.

2011

Abstract Background The hippocampal formation has been implicated in etiology and therapy response in major depressive disorder (MDD). However, prospective longitudinal studies investigating volumes in hippocampal subregions and their association with clinical findings are still lacking. Methods Global and regional hippocampal volumes and neuropsychological performance were assessed longitudinally in 15 young patients with unipolar early onset MDD who responded to therapy and 13 matched healthy control subjects. Results Although volumes at baseline did not differ between groups, patients with MDD showed significant posterior hippocampal volume increases during the treatment course (mean obs…

AdultMalemedicine.medical_specialtyHippocampusHippocampal formationNeuropsychological TestsHippocampusYoung AdultInternal medicineNeuroplasticitymedicineHumansLongitudinal StudiesProspective StudiesDepressive Disorder MajorNeuronal PlasticityNeuropsychologyOrgan SizeMiddle Agedmedicine.diseaseMagnetic Resonance ImagingAntidepressive AgentsPsychiatry and Mental healthClinical PsychologyCase-Control StudiesEtiologyCardiologyHippocampal volumeAntidepressantMajor depressive disorderFemalePsychologyNeuroscienceJournal of affective disorders
researchProduct

Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study.

2016

Aims.In recent years several warnings have been issued by regulatory authorities on the risk of electrocardiogram abnormalities in individuals exposed to psychotropic drugs. As a consequence of these warnings, monitoring of the QT interval corrected for heart rate (QTc) has become increasingly common. This study was conducted to measure the frequency of QTc prolongation in unselected psychiatric patients, and to document the associated factors using a cross-sectional approach.Method.The study was carried out in 35 Italian psychiatric services that are part of the STAR (Servizi Territoriali Associati per la Ricerca) Network, a research group established to produce scientific knowledge by col…

AdultMalemedicine.medical_specialtyPsychotropic drugsEpidemiologymedicine.medical_treatmentLong QT syndromeAntidepressantDrug overdoseAdverse effectQT intervalAntipsychotic03 medical and health sciencesElectrocardiography0302 clinical medicineRisk FactorsPsychotropic drugmedicinePrevalenceHumanscardiovascular diseasesAntipsychoticAdverse effectPsychiatrySettore MED/25 - PsichiatriaPolypharmacybusiness.industryEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Epidemiology; Public Health; Environmental and Occupational Health; Psychiatry and Mental HealthOriginal Articlesmedicine.diseaseAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Epidemiology; Public Health Environmental and Occupational Health; Psychiatry and Mental Health030227 psychiatrySubstance abuseLong QT SyndromeCross-Sectional StudiesItalyPsychiatry and Mental HealthPolypharmacyAripiprazoleFemalePublic HealthbusinessAntidepressant; adverse effect; antipsychotic; psychotropic drugsAdverse effect; Antidepressant; Antipsychotic; Psychotropic drugs; Adult; Antipsychotic Agents; Cross-Sectional Studies; Electrocardiography; Female; Humans; Italy; Long QT Syndrome; Male; Prevalence; Risk Factors; Polypharmacy; Epidemiology; Public Health Environmental and Occupational Health; Psychiatry and Mental Health030217 neurology & neurosurgerymedicine.drugAntipsychotic AgentsEpidemiology and psychiatric sciences
researchProduct

Therapeutic Drug Monitoring of the Antidepressant Mirtazapine and Its N-Demethylated Metabolite in Human Serum

2004

Mirtazapine is a novel antidepressant that acts by enhancing serotonergic and noradrenergic neurotransmission. Because very little is known about serum concentrations in relation to clinical effects, the use of therapeutic drug monitoring is so far unclear. A rapid automated HPLC method with fluorescence detection was developed for routine quantification of mirtazapine and its demethylated metabolite N-desmethylmirtazapine in human serum. The precision of the method was suitable because the day-to-day (n = 7) coefficient of variation (CV) of mirtazapine was 9.8, 4.2, and 5.1% for concentrations of 10, 40, and 80 ng/mL, respectively, and the CV for N-desmethylmirtazapine were 11.6, 10.3, and…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentMetaboliteCoefficient of variationMirtazapineMirtazapineMianserinPharmacologySensitivity and Specificitychemistry.chemical_compoundInternal medicinemedicineHumansPharmacology (medical)AmisulprideAntipsychoticChromatography High Pressure LiquidAgedPharmacologySertralinemedicine.diagnostic_testbusiness.industryMiddle AgedEndocrinologychemistryTherapeutic drug monitoringHistamine H1 AntagonistsAntidepressantFemaleDrug Monitoringbusinessmedicine.drugTherapeutic Drug Monitoring
researchProduct

GRANULOMATOUS MASTITIS DURING CHRONIC ANTIDEPRESSANT THERAPY: IS IT POSSIBLE A CONSERVATIVE THERAPEUTIC APPROACH?

2012

Granulomatous mastitis is a rare benign inflammatory disease of the breast with multiple etiologies such as tuberculosis, sarcoidosis, foreign body reaction, and mycotic and parasitic infections. In contrast, idiopathic granulomatous mastitis (IGM) is characterized by the presence of chronic granulomatous lobulitis in the absence of an obvious etiology. Clinically and radiologically it may mimic breast carcinoma and so awareness of surgeons, pathologists, and radiologists is essential to avoid unnecessary mastectomies. Cases of IGM are reported during antidepressant therapy in patients also showing high levels of prolactinemia. In these cases, we believe that surgical excision must be avoid…

Antidepressant therapyCancer Researchmedicine.medical_specialtyTuberculosisbusiness.industryDiseaseGranulomatous mastitismedicine.diseaseBrief CommunicationDermatologySurgeryHyperprolactinemiaTherapeutic approachSettore MED/18 - Chirurgia GeneraleBreast cancerOncologySelective serotonin reuptake inhibitorsmedicineEtiologySarcoidosisantidepressant therapy idiopathic granulomatous mastitis selective serotin reuptake inhibitorsIdiopathic granulomatous mastitisbusinessPathological
researchProduct

FGFR1-5-HT1A receptor heterocomplexes: relevance for neuroplasticity and depression

2014

Antidepressants: basic Depression: basic ReceptorsSettore BIO/09 - Fisiologia
researchProduct